Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab-Reference-Cited by-同舟云学术

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Published:2017-12-07 Issue:1 Volume:70 Page:60-68
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Tweehuysen Lieke¹,Bemt Bart J. F.²,Ingen Iris L.³,Jong Alphons J. L.⁴,Laan Willemijn H.⁵,Hoogen Frank H. J.²,Broeder Alfons A.²

Affiliation:

1. Sint Maartenskliniek Nijmegen The Netherlands

2. Sint Maartenskliniek and Radboud University Medical Center Nijmegen The Netherlands

3. Radboud University Medical Center Nijmegen The Netherlands

4. Rijnstate Arnhem The Netherlands

5. Maartenskliniek Woerden The Netherlands

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40324

Reference29 articles.

1. European Medicines Agency.Remsima (infliximab). October 2013. URL:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/human_med_001682.jsp&mid=WC0b01ac058001d124.

2. European Medicines Agency.Inflectra (infliximab). October 2013. URL:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/human_med_001677.jsp&mid=WC0b01ac058001d124.

3. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

4. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

5. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry;The Journal of Rheumatology;2024-06-01

2. Nocebo effects in systemic therapies for adult plaque psoriasis: A systematic review and meta-analysis;Frontiers in Medicine;2024-03-27

3. Biosimilars;Journal of Infusion Nursing;2024-01

4. Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-11-23

5. Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?;2023-11-07